NYSE:CRLLife Sciences
Should Higher Impairments and AI Investments Shape a New Capital Allocation Playbook for Charles River (CRL)?
In May 2026, Charles River Laboratories reported first-quarter revenue of US$995.83 million with a net loss of US$14.84 million, raised full-year GAAP EPS guidance to US$5.35–US$5.85, completed a US$200 million buyback, and detailed higher long-lived asset impairments alongside continued investment in AI-enabled digital pathology and cell therapy testing collaborations.
These updates highlight Charles River’s effort to reshape its business mix and efficiency profile, using automation,...